Compare Novavax Inc (NVAX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Financial Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Financial Select Sector SPDR Fund trades at $57.79. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | XLF | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | — |
52-Week High | $11.19 | $58.01 |
52-Week Low | $6.22 | $47.80 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
XLF trades at $57.88, up 0.12% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF recently crossed above its 200-day moving average, indicating positive momentum. Recent news highlights strong inflows into sector ETFs and potential opportunities from AI infrastructure financing.
The outlook for XLF is supported by technical strength and sector tailwinds, but overbought RSI levels suggest near-term caution. Key risks include interest rate sensitivity and market volatility. Analyst sentiment is generally positive, focusing on the financial sector's role in economic growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
